Literature DB >> 11154163

Management of severe gastroesophageal reflux disease.

J A DiPalma1.   

Abstract

Gastroesophageal reflux disease (GERD) affects more than one third of the population. It is generally a chronic condition and has the potential to be serious. Some patients with GERD experience persistent daytime or nighttime heartburn and some sustain severe damage, including ulceration, stricture, and Barrett's esophagus, which can predispose to development of adenocarcinoma. Extraesophageal manifestations of GERD can include otolaryngologic, respiratory, and cardiac problems. Severe GERD responds best to agents that suppress gastric acid secretion. Of these, proton pump inhibitors (PPIs) provide the most effective control of gastric acidity and are, therefore, the medical treatment of choice. In fact, nonresponse to a PPI should raise the suspicion that the diagnosis is not GERD. Proton pump inhibitors are quickly becoming the treatment of choice for GERD, especially for severe or refractory cases. For patients whose GERD is refractory even to PPIs or who are unwilling to face years of PPI therapy, antireflux surgery remains an option.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154163     DOI: 10.1097/00004836-200101000-00006

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  Intravenous lansoprazole: in erosive oesophagitis.

Authors:  Toni M Dando; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Intravenous esomeprazole.

Authors:  Gillian M Keating; David P Figgitt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Treatment of gastroesophageal reflux disease.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12

5.  Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.

Authors:  Jasper Hein
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 6.  Esomeprazole: in gastroesophageal reflux disease in children and adolescents.

Authors:  Jamie D Croxtall; Caroline M Perry; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

Review 7.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

9.  Esomeprazole: a review of its use in the management of acid-related disorders in the US.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Esomeprazole: a review of its use in the management of acid-related disorders.

Authors:  Lesley J Scott; Christopher J Dunn; Gordon Mallarkey; Miriam Sharpe
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.